No Data
No Data
Is Passage Bio (NASDAQ:PASG) In A Good Position To Invest In Growth?
Expanding Market and Promising Preclinical Results Bolster Buy Rating for Passage Bio
Passage Bio Advances on FDA Feedback for Dementia Treatment
Express News | Passage Bio Receives Positive Feedback From FDA On Expansion Of UpliFT-D Trial Of PBFT02 To Treat Frontotemporal Dementia (FTD)
Express News | Passage Bio Inc - to Initiate Dosing of Ftd-C9Orf72 Patients in 1H 2025
Express News | Passage Bio Announces Positive Feedback From FDA on Expansion of Uplift-D Trial of Pbft02 to Include Ftd-C9Orf72 Patients
No Data